April 23, 2024
Bunge-Viterra agriculture merger runs into Canada competition concerns
By David Ljunggren and Rod Nickel
Best Free US Stock Signals for 2024
By David Ljunggren and Rod Nickel
As the Q4 FY24 earnings season is going on, Goldman Sachs (NYSE:GS) analysts have recalibrated their projections for the Indian pharmaceutical sector, factoring in a spectrum of variables from monthly sales data to currency fluctuations. Notably, the sector continues to trade at valuations exceeding one standard deviation above its five-year average, largely propelled by the resilience of major players like Sun Pharma (NS:SUN), Cipla (NS:CIPL), and Divi’s Laboratories.